The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission ...

Daniel L. Forman of Lowenstein Sandler LLP discusses key disclosure considerations for securities 10-K filings as companies ...

The bot, which will be available for preorder this year, walks, talks, washes dishes and clothes, makes sandwiches and pours ...

Tiziana Life Sciences Ltd., a biotechnology company pioneering breakthrough immunomodulation therapies, has entered a ...

The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and ...

Colossal Biosciences cofounder and CEO Ben Lamm is worth $3.7 billion following the company's recent fundraise at an ...

What considerations should developers in Denver-Boulder keep in mind when planning future life sciences facilities, particularly around the flexibility required for evolving technologies?

By owning a substantial senior housing operating portfolio, Ventas has unlocked value in its most favorable assets, but this also leads to a greater degree of volatility and financial risk versus the ...

Amicus Therapeutics has two products in the market that generated more than $528 million in revenue last year.

Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

The company’s CLIA-certified lab in Irvine, California, is licensed by the California Department of Public Health and will perform the test.